Mach7 Technologies Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TDMMF research report →
Price Chart
About the company
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients’ medical images; vendor-neutral archive (VNA), a vendor-agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. The company also provides workflow applications, such as a universal worklist, quality control (QC) tools designed for technologists’ workflows; image sharing and exchange capabilities; teleradiology services; and additional specialized tools to serve departmental patient care needs.
- CEO
- Teri Thomas
- IPO
- 2015
- Employees
- 296
- HQ
- South Burlington, VT, US
Get TickerSpark's AI analysis on TDMMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $38.58M
- P/E
- -6.71
- Fwd P/E
- 96.77
- PEG
- 0.11
- P/S
- 2.15
- P/B
- 1.73
- EV/EBITDA
- -34.02
- Div Yield
- 0.00%
- Gross Margin
- -6.76%
- Op Margin
- -27.66%
- Net Margin
- -31.99%
- ROE
- -24.29%
- ROIC
- -20.19%
Latest fiscal year · YoY change
- Revenue
- $27.87M-17.5%
- Gross Profit
- $-1,884,785-122.5%
- Op Income
- $-7,708,689
- Net Income
- $-8,916,043-43.8%
- EPS
- $-0.04-47.3%
- OCF Growth
- -245.3%
- FCF Growth
- -1279.0%
- 52W High
- $0.50
- 52W Low
- $0.14
- 50D MA
- $0.16
- 200D MA
- $0.22
- Beta
- 0.97
- RSI (14)
- 42
- Avg Volume
- 882
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mach7 delivered its fourth straight quarter of positive operating cash flow, while ARR grew and management pointed to a broader product reset aimed at turning product innovation into more recurring revenue.· October 25, 2026
- Positive operating cash flow was $0.3 million, versus a $3.7 million outflow a year ago, marking the fourth consecutive positive quarter.
- Customer receipts rose to $7.3 million, up 58%, while operating payments fell 17% to $7 million as the FY '26 restructuring savings held.
- ARR run rate was $23.5 million, up 8.5% in constant currency; CARR was $25.3 million, down 7.4% due mainly to the Veterans Health Administration ending its NTP project.
- Management emphasized Flamingo, a new modular product suite, with five connected capabilities and early adopters expected to start installing modules early next year.
- Cash ended at $19.3 million with no debt, and the company said it is funding higher product investment from internal resources.
Mach7 reported positive operating cash flow of $0.3 million for the September quarter, versus an outflow of $3.7 million in the same quarter last year. Customer receipts were $7.3 million, up 58% from $4.6 million, and operating payments were $7 million, down 17% year over year. Cash ended at $19.3 million with no debt, down $0.6 million from 30 June and up from $18.9 million a year ago. ARR run rate was $23.5 million, up 8.5% in constant currency, while CARR was $25.3 million, down 7.4% in constant currency. Management did not provide formal guidance, but said FY '26 savings are expected to hold, R&D capitalization should continue at a similar level in FY '27, and CARR should improve as new modules and new contracts convert pipeline into signed business.
Teri Thomas framed the quarter as proof that Mach7’s reset is taking hold, citing four consecutive quarters of positive operating cash flow, rising ARR, and stronger customer engagement. She said the company is moving from internal rebuilding to growth, with Flamingo designed to expand the product set, simplify buying, and help customers adopt new capabilities incrementally. Her tone was optimistic but disciplined: she repeatedly stressed that the business still has more to prove in revenue growth and new customer wins.
Shawni Hadfield focused on cash generation, cost discipline, and the effect of the restructuring. She said the quarter’s $0.3 million operating cash inflow came from higher receipts and lower payments, with staff costs down from $6 million to $4.7 million and administration/corporate costs down from $2 million to $1.2 million. She also noted $0.7 million of capitalized development, up from $0.3 million last year, and said cash at quarter-end was $19.3 million with no debt; she expects the FY '26 cost savings to hold and R&D capitalization to remain at this level in FY '27.
Analysts asked about FY '27 OpEx and capitalized R&D, and management said it is not giving guidance, but expects the FY '26 cost base savings to hold and R&D capitalization to continue at roughly this level. On the ARR versus CARR gap, Shawni said CARR fell mainly because the Veterans Health Administration NTP project was removed, and she expects CARR to rise as new modules and new contracts come through the pipeline. On cash collections, she said the reset in billing and administrative processes is now sustainable, though cash flow will still be lumpy because of annual billing and differing payment terms, including some new customers paying quarterly.
The call showed clear operational improvement: positive operating cash flow, higher receipts, lower costs, and a cash balance of $19.3 million with no debt. Management believes Flamingo and broader product modernization can create more recurring revenue, open new customer relationships, and drive module-based expansion across the installed base. Teri Thomas also said the company is poised to show the new modules at RSNA and has four large customers lined up as early adopters.
CARR declined 7.4% in constant currency, with management attributing much of the drop to the loss of the Veterans Health Administration NTP project, showing the pipeline still has some concentration risk. Management did not provide financial guidance, and Thomas said shareholders still need to see progress in revenue growth and new customer wins. Cash flow is also still somewhat lumpy because of annual billing cadence and changing payment terms, even if management believes collections are now sustainable.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.2%
- Shares Outstanding
- 235.01M
- Float Shares
- 200.14M
Our TDMMF coverage
Recent articles, reports, and earnings notes.
No research on TDMMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TDMMF report →Mach7 Technologies Limited (TDMMF) Q1 2027 Earnings Call Transcript
seekingalpha.com · Oct 25
Mach7 Technologies Limited (TDMMF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Aug 28
Mach7 Technologies Limited (TDMMF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Jul 29
Mach7 Technologies to Showcase Enterprise Imaging Innovation and New eUnity Digital Pathology Capabilities at SIIM26
prnewswire.com · Jun 1
Mach7 Technologies Limited (TDMMF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Apr 23
Mach7 Technologies Limited (TDMMF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Feb 27
Mach7 Technologies Limited (TDMMF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jan 29
Mach7 Technologies Limited (TDMMF) Shareholder/Analyst Call Transcript
seekingalpha.com · Nov 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.